Ranirestat for the management of diabetic sensorimotor polyneuropathy
about
Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function.Four-year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetesBaicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters.The evolving natural history of neurophysiologic function in patients with well-controlled diabetes.AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.The effects of capillary dysfunction on oxygen and glucose extraction in diabetic neuropathy.Update on the management of diabetic polyneuropathies.Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathyEffect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study.Emerging drugs for diabetic neuropathy.Diabetic neuropathy: cellular mechanisms as therapeutic targets.Whither pathogenetic treatments for diabetic polyneuropathy?Diabetic neuropathy and oxidative stress: therapeutic perspectives.Evaluation of ranirestat for the treatment of diabetic neuropathy.Neurologic complications of diabetes.Efficacy of α-lipoic acid in diabetic neuropathy.Emerging drugs for diabetic peripheral neuropathy and neuropathic pain.The wound/burn guidelines - 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene.Antioxidant strategies in the management of diabetic neuropathy.NHC-Catalyzed Asymmetric Synthesis of Functionalized Succinimides from Enals and α-Ketoamides.Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.Metabolic Syndrome and Neuroprotection.
P2860
Q30239828-BF2C3630-0F2E-42AF-A828-90037FB47E6BQ33633642-C8C2EDF9-26C9-4AE3-9162-329677E7CAAAQ34434392-E50CB17C-2EEE-4A66-9341-1068129420E8Q34637674-3CC33980-AEC0-4431-921E-DA646B16D19BQ34777951-C6FDAE8A-0E63-497D-9DDE-F82F28F1FB3CQ35141326-F8EEBED7-2734-41E1-9BDA-F23D7682551FQ35153023-CC7BC661-1DFD-4284-9065-D6C6192CAAE4Q35178801-FAAD7760-B71D-40CD-87EB-964D1441002DQ35179226-595C299F-A3C2-4B42-9FE0-FD10523544BAQ35179957-03C661D5-EF11-4C65-ADBE-B93CA4711A9EQ36293649-B1A01C05-BB2F-42BF-BB13-64A92E695863Q36329924-F2B6E6B7-07ED-4E33-AEA7-86D84441AC56Q36532024-AA6E960E-15DC-4408-8DF4-3EE7DB701708Q37783301-1FC12E08-7AEB-4833-A20E-8D2B0D8F2B9AQ37930962-4C6127E8-CF9C-4301-936C-2F861C3EDD8EQ38079186-1E73E5BA-E2F9-4D15-833A-E7C6D1A1E57DQ38112117-C35AF1FC-62B8-458E-8702-5FBE608F2446Q38208484-67F0A11A-4BB4-4A87-BB1E-5479039D55E2Q38210942-5B7B8579-7E71-42C3-B7A5-14EDEFD9A4D6Q38266297-6B524960-AFD8-4D11-A987-5D5EAB9C8813Q38798588-E96A5C09-FB1D-4DFD-8C99-E10E61E68792Q40757188-BE81CF6D-6C0B-4B71-80B3-64A84910B36AQ42180667-279B55B9-D800-48CD-AB17-44F3A7D93390Q43170728-DC625EF1-36C5-4299-8F6B-F02EF85DF6F9Q46207930-86D09831-1868-43CA-92D5-907C18745442Q47978551-64AC7803-6E6E-45F9-9B63-52BDB9055783Q53687232-F768AC1B-31B8-4858-BF60-844CB6D97A3F
P2860
Ranirestat for the management of diabetic sensorimotor polyneuropathy
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Ranirestat for the management of diabetic sensorimotor polyneuropathy
@ast
Ranirestat for the management of diabetic sensorimotor polyneuropathy
@en
Ranirestat for the management of diabetic sensorimotor polyneuropathy
@nl
type
label
Ranirestat for the management of diabetic sensorimotor polyneuropathy
@ast
Ranirestat for the management of diabetic sensorimotor polyneuropathy
@en
Ranirestat for the management of diabetic sensorimotor polyneuropathy
@nl
prefLabel
Ranirestat for the management of diabetic sensorimotor polyneuropathy
@ast
Ranirestat for the management of diabetic sensorimotor polyneuropathy
@en
Ranirestat for the management of diabetic sensorimotor polyneuropathy
@nl
P2093
P2860
P356
P1433
P1476
Ranirestat for the management of diabetic sensorimotor polyneuropathy
@en
P2093
Robert Buchanan
Sasagu Tomioka
Toshiyuki Hirose
P2860
P304
P356
10.2337/DC08-2110
P407
P50
P577
2009-07-01T00:00:00Z